Tirzepatide (Mounjaro®) pricing: Information for pharmacy owners

Eli Lilly has announced plans to increase the NHS list prices of all strengths of Tirzepatide (Mounjaro®) from 1st September 2025, which will impact on the dispensing of NHS prescriptions by community pharmacies.

Community Pharmacy England is urgently seeking assurances from the Department of Health and Social Care (DHSC) that reimbursement of NHS prescriptions (branded or generically written) for Mounjaro® dispensed from September will reflect the new, higher list prices.

In the past, following representations from Community Pharmacy England, DHSC has made exceptions to the price change mechanism when adjusting the reimbursement prices for certain branded products – for example, the recently announced retrospective reimbursement prices for June and July 2025. We are expecting DHSC will grant a similar exception for Mounjaro® prescriptions dispensed in September, and hope to be able to make an announcement on this shortly.

Please note:  We understand there are growing concerns regarding Mounjaro® pricing and supply arrangements for private services offered by many pharmacies. However, Community Pharmacy England’s remit is restricted to NHS pharmacy services and we are therefore unable to address queries relating to the private supply of Mounjaro®.

Suraj Shah, Drug Tariff and Reimbursement Manager at Community Pharmacy England, said:

“The announcement of substantial price increases for Tirzepatide (Mounjaro®) is a significant worry for pharmacy teams and patients alike. As soon as news broke, Community Pharmacy England began seeking assurance from DHSC that reimbursement of NHS prescriptions dispensed from September will reflect the higher prices.

No one yet knows the full extent of the impact the change will have on community pharmacies, but we are already aware of a surge in demand ahead of September’s planned increase. The Government must look to both maintain UK supply and protect pharmacies from any knock-on effects.”